RO6874281
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RO6874281, covering 2024-10-03 to 2024-10-03. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma [Phase 1]